Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Nephrology·MeSH: Polycystic Kidney, Autosomal Dominant
Prevalence
30.0 / 100K
6 drugs in development·2 companies·5 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| bardoxolone | REATA PHARMACEUTICALS INC (RETA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Autosomal Dominant Polycystic Kidney Disease (ADPKD)?
BioSniper tracks 6 drugs in development for Autosomal Dominant Polycystic Kidney Disease (ADPKD) across 2 companies.
How many clinical trials target Autosomal Dominant Polycystic Kidney Disease (ADPKD)?
There are 5 clinical trials targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD) tracked by BioSniper.
What is the prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD)?
The estimated prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) is approximately 30.0 per 100,000 population.
Deep-dive into Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis